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Monday, March 7, 2011 295amitochondria CRC (287517 vs. 180512 nM/mg mitochondrial protein,
p<0.05), but it had no effect on CRC from mitochondria of GPER-/- hearts
(170533 vs. 16757 nM/mg mitochondrial protein). These results conclu-
sively demonstrate that GPER plays an important role in mediating rapid
E2-induced cardioprotection after ischemia/reperfusion. Supported by NIH.
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Validation of Reperfusion Duration for Myocardial Infarction Assessment
in the Langendorff Ischemia Model of Isolated Mouse Heart
Jean Chrisostome Bopassa, Ligia Toro, Enrico Stefani.
Introduction: Perfused isolated heart is a widely used ex-vivo organ model as it
allows rigorous control of parameters what is not readily achievable by an in
vivo model. However, there is disagreement on the reperfusion duration to as-
sess the myocardial infarction by TTC staining. Many authors have used long
reperfusion times (~120 min) in conditions where the hearts during ischemia
were suspended in air water-jacketed chamber maintained at37C. Others
have determined myocardial infarction with short reperfusion durations
(30-40min) where the hearts were submerged in a normothermic physiological
solution. In this work where hearts were immersed in Krebs Henseleit (KH) so-
lution during ischemia we demonstrated that a reperfusion duration of 40 min is
adequate to determine infarct size after ischemia as longer reperfusion times of
60 and 90 min showed the same maximal infarct size.
Methods and Result:We compared different reperfusion durations (40, 60 and
90 min) of isolated mice hearts immersed in KH buffer after 18 min of normo-
thermic ischemia. Hearts were perfused using Langendorff apparatus with KH
buffer oxygenated with 95% O2 þ 5% CO2 at37C. The heart function was
recorded and myocardial infarction assessed by TTC staining at the end of
reperfusion. Our data show no significant difference between the groups reper-
fused for 40, 60 or 90 min in infarct size and heart function recovery.
Conclusion: These results indicate that when the isolated mice hearts are im-
mersed in a normothermic physiological solution during ischemia, reperfusion
for 40 min is sufficient to reach the maximum infarction.
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Ivabradine and Mechanical Unloading Increase Sarcoplasmic Reticulum
Calcium Content in a Rodent Model of Heart Failure
Manoraj Navaratnarajah, Carin van Doorn, Urszula Siedlecka,
Michael Ibrahim, Ajay Gandhi, Adarsh Shah, Magdi H. Yacoub,
Cesare M. Terracciano.
Improvements in Ca2þ handling, and sarcoplasmic reticulum (SR) Ca2þ
regulation in particular, are associated with myocardial recovery in patients
with end stage heart failure (HF) treated with left ventricular assist devices
(LVAD). Ivabradine (IV), a novel heart rate reducing agent has been shown to
have positive Ca2þ regulatory effects in rodent HF, and is used in human HF ther-
apy; however, the effects of IV during LVAD treatment have not been studied.
We studied the chronic effects of IV on cellular Ca2þ handling during mechan-
ical unloading (MU) of HF hearts. HF was induced by left coronary artery
ligation and was characterized by reduced ejection fraction (EF), smaller
Ca2þ transient amplitude (CaT) and reduced SR Ca2þ content compared to
age matched sham operated animals (SH). MU (4 weeks) was achieved by
heterotopic abdominal heart transplantation and IV (10mg/kg/day) was admin-
istered for 4 weeks. Isolated ventricular myocytes were loaded with Indo-1 AM
and field stimulated at 1 Hz.
CaT was significantly elevated in the MUþIV group (indo-1 ratio units):
MUþIV: 0.25 5 0.06 (n=45) p< 0.001 vs MU: 0.18 5 0.05 (n=40), and
p<0.001 vs SH: 0.175 0.05 (n=45)). IV augmented SR Ca2þ content in com-
bination with MU compared with MU alone and to a level even greater than
SH: SR Ca2þ content (indo-1 ratio units): MUþIV: 0.27 5 0.07 (n=45) p<
0.05 vs MU: 0.245 0.05 (n=40), and p<0.001 vs SH: 0.225 0.07 (n=45))
Our results show that IV treatment combined with mechanical unloading
induces a larger increase of Ca2þ transient amplitude and SR Ca2þ content
compared with mechanical unloading alone. These effects may be exploited
to enhance myocardial recovery in patients receiving LVAD therapy for HF.
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Bioenergetic Supply and Demand in the Cardiomyocyte
Edmund J. Crampin.
The mechanisms that regulate the control of energy demand and supply in the
myocardium are crucial for maintaining normal cardiac function. Although
a number of mechanisms have been proffered by which mitochondrial supply
of ATP can change to match varying workload in the myocardium, identifying
the underlying regulatory pathways remains controversial.
We describe an approach to studying this problem in which thermodynamically
consistent mathematical models of the key energy-consuming processes in the
cardiomyocyte (sarcoplasmic endoplasmic reticulum calcium ATPase
(SERCA)[1], sodium pump[2] and the acto-myosin cross-bridge cycle[3]) arecoupled to a model of mitochondrial ATP production within a whole-cell mod-
elling framework for cardiac excitation-contraction coupling[4].
We use the model to investigate the metabolic stability hypothesis, wherein en-
ergy demand-supply homeostasis is maintained despite negligible variation in
metabolite concentrations at varying cardiac workloads. We find that under
physiological workloads cellular metabolite concentrations do not change
significantly with increasing workload if a proposed feedback of inorganic
phosphate onto mitochondrial oxidative phosphorylation is present, consistent
with the proposition that Pi-regulation alone is sufficient to maintain metabolic
homeostasis in the absence of other regulatory mechanisms.
Finally, we use our model to address the empirically observed linearity of the
cardiac ATP vs. Force-Length-Area curve (the cellular equivalent of the VO2
vs. Pressure-Volume-Area relationship). We show that the apparent linearity
arises from the near irreversibility of the cross-bridge cycle, but that the linear
relationship may disappear at cardiac workloads high enough that cellular
metabolite concentrations start to vary.
[1] Biophysical Journal 96, 2029-2042, 2009
[2] American Journal of Physiology, Heart and Circulatory Physiology 293,
H3036-H3045, 2007
[3] Biophysical Journal 98, 267-276, 2010
[4] Biophysical Journal 90, 3074-3090, 2006
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Stimulation of Cardiac Neoangiogenesis by Estrogen Therapy is One of the
Key Mechanisms in Reversing Advanced Heart Failure
Andrea Iorga, Rod Partow-Navid, Humann Matori, Rangarajan Nadadur,
Jingyuan Li, Soban Umar, Mansoureh Eghbali.
Estrogen(E2) has been shown to regulate angiogenesis in different tissues, but it
is still not known if E2 could stimulate angiogenesis in the heart. Recently, we
showed that E2 rescues advanced heart failure by reversing the myocardial
contractile deficiency and restoring ejection fraction from ~30% to ~55%.
Here we examined whether stimulation of angiogenesis in the heart is a mech-
anism involved in the E2-induced rescue of HF. Trans-aortic constriction(TAC)
procedure was used to induce HF. Once the ejection fraction(EF) reached
~30%, one group of mice was sacrificed and the other two groups were treated
with E2(30 mg/kg/day, n=16), or E2 plus the angiogenesis inhibitor TNP-470
(TNP, 30 mg/kg, n=4) for 10 days. Serial echocardiography, real-time PCR
and immunocytochemistry were performed. RT-PCR showed that the transcript
levels of two markers of angiogenesis, vascular endothelial growth factor
(VEGF) and hypoxia-inducible factor-1a(HIF1a), were ~10 fold downregulated
in HF(0.1750.06 for VEGF and 0.2650.01 for HiF1a; normalized to CTRL).
E2 treatment was not only able to reverse VEGF and HIF1a transcript level
downregulation observed in HF, but to even upregulate both transcripts 3
fold higher than in healthy controls(3.2450.1 for VEGF and 3.1650.09 for
HIF1a). Quantification of capillary density also revealed that E2 therapy not
only completely reversed the loss of capillaries in HF, but significantly en-
hanced capillary density by ~ 4 fold compared to HF(2.8350.14 in E2 vs.
0.6650.07 in HF, normalized to CTRL). Interestingly, E2 failed to rescue
HF in the presence of TNP-470 (E2þTNP group) as EF (29.352.1%) was
not significantly improved after 10 days of therapy. The capillary density of
HF mice also did not improve in E2þTNP group(0.5350.07). These data
strongly support the vital role of angiogenesis in the rescue action of E2.
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Estrogen Receptor Beta, but Not Alpha, is the Key Player in Restoration
of Heart Function of Heart Failure Mice by Estrogen Therapy
Andrea Iorga, Rod Partow-Navid, Rangarajan Nadadur, Humann Matori,
Jingyuan Li, Soban Umar, Mansoureh Eghbali.
Recently we discovered that estrogen(E2) therapy can rescue advanced heart
failure(HF) induced by pressure overload in mice. Most of the biological
actions of estrogen are mediated thorough estrogen receptors alpha(ERa) and
beta(ERb), and both of these receptors are present in the heart. Here we inves-
tigated which estrogen receptor(s) are involved in the rescue by estrogen. We
used the transaortic constriction(TAC) procedure to induce HF. Once the ejec-
tion fraction(EF) reached ~30%, one group of animals was sacrificed(HF
group), and the other three groups received either 17b-estradiol (30 ug/kg/
day), selective ERa agonist (PPT, 0.625mg/kg/day), or selective ERb agonist
(DPN, 0.625mg/kg/day) for 10 days. Serial echocardiography was performed
and LV pressure was measured by direct catheterization before sacrifice. As ex-
pected, E2 rescued HF by restoring EF from 33.1751.12% to 53.0551.29%.
Interestingly, mice treated with ERb agonist had a significant improvement in
their EF from 33.1751.12% to 45.2552.1%(n=7), whereas the EF of mice
treated with ERa agonist did not improve at all(31.0952.3%, n=6). Similar
to EF, only fractional shortening of DPN-treated mice improved from
15.750.58% in HF to 21.9551.65% in DPN vs. 14.7251.24% in PPT).
Next, we examined the mechanical performance of the LV in mice treated
